Predictability of microkeratome-dependent flap thickness for DSAEK.

BACKGROUND: The recommended thickness of the graft lamella in Descemet's stripping automated endothelial keratoplasty (DSAEK) is 120 - 180 microm. To adjust for the large variation in central corneal thickness (CCT) of eye bank donor corneas, microkeratome plates of different heights are available. The aim of this study was to evaluate the lamella thickness predictability of different keratome plates in a clinical routine setting. METHODS: In a prospective study of 60 consecutive DSAEK procedures, CCT was measured with a 50 MHz ultrasound pachymeter after meticulous epithelium removal immediately before and after lamella creation. Selected plate thickness was 300, 350, or 400 micro, respectively. Cutting depth was calculated by subtracting the remaining CCT of the deep lamella after the cut from the initial CCT before the cut. RESULTS: The mean (+/- SD) cutting depth was 320 +/- 45 microm with the Amadeus 350 keratome, 317 +/- 48 microm with the Moria 300 keratome, 388 +/- 58 microm with the Moria 350 keratome and 467 +/- 94 microm with the Moria 400 keratome. Neither the duration nor the type of donor preservation had an effect on the accuracy of the cutting depth. CONCLUSION: The mean cutting depth for the DSAEK keratomes is more accurate than the cutting depth of the same keratome heads designed for LASIK. This might be due to the fact that DSAEK lamellas were cut after complete epithelial removal. Despite the accurate mean cutting accuracy, there is a substantial variation between individual cuts which have to be taken into consideration.

[Safety of treatment with tacrolimus ointment for anterior segment inflammatory diseases]. / Sicherheit der Behandlung entzündlicher Vorderabschnittserkrankungen mit Tacrolimus-Salbe.

BACKGROUND: The off-label use of topical tacrolimus (Protopic) for inflammatory external eye diseases is gaining popularity. However, there are no reports on the safety profile of this new treatment option. PATIENTS AND METHODS: We treated six patients with different inflammatory eye diseases with topical tacrolimus (Protopic 0.03 %) as off-label use in addition to the conventional anti-inflammatory treatment. Patients were interviewed for side effects and serum drug concentrations were measured under steady state conditions one hour after topical application of tacrolimus ointment. RESULTS: Two patients reported a slight burning sensation immediately after application, in one patient we found a slight worsening of the dry eye problems. No patient abandoned the treatment due to side effects. Serum drug concentrations remained below the analytical threshold in all cases (< 1.5 ng/ml). CONCLUSIONS: Tacrolimus for the topical treatment of anterior segment inflammatory eye diseases is well tolerated without detectable systemic drug resorption.

In vivo confocal microscopy of keratic precipitates in fuchs heterochromic uveitis syndrome.

BACKGROUND: In vivo confocal microscopy (IVCM) enables large-field in vivo examination of the corneal endothelium and corneal precipitates. Keratic precipitates (KP) are prominent features of Fuchs Heterochromic uveitis syndrome (FHUS). The aim of this study was to investigate the effect of KP on the corneal endothelium. PATIENTS AND METHODS: Eight patients with clinically diagnosed FHUS and KP between July 2007 and May 2008 underwent slit lamp examination and IVCM. KP (shape, area), endothelial cell count and percentage of hexagonal cells were measured and compared with an age-matched control group and with not affected healthy contralateral eyes. RESULTS: The age of participants ranged between 26 and 67 years. KP had a diameter ranging between 37 to 217 microm (mean 137 microm) with an average area of KP of 5630 microm (2). The mean endothelial cell count in the study group was 2541 +/- 299 cells/mm (2), 2722 +/- 312 cells/mm (2) in the control group (p = 0,18) and 2397 +/- 192 cells/mm (2) in not affected contralateral eyes (p = 0.17). The percentage of hexagonal cells was 59.1 % in FHUS study group and 69.1 % in the control group (p = 0.0002) and 68.6 % in not affected contralateral eyes (p = 0.0495). CONCLUSIONS: KP in FHUS cause a focal damage of endothelial cells reflected in a decreased percentage of healthy hexagonal cells. The degree of endothelial cell damage seems to be low as it does not lead to a significant reduction in the endothelial cell count.

["Floaterectomy"--pars-plana-vitrectomy for vitreous opacities]. / "Floaterektomie"--Pars-Plana-Vitrektomie wegen Glaskörpertrübungen.

BACKGROUND: Patients suffer from vitreous opacities, despite good visual acuity. The lack of objective measurements may make it difficult to justify the indication for vitreous surgery. PATIENTS AND METHODS: We analysed retrospectively the outcome of 90 eyes/ 67 patients, age 20 - 86 years (mean 60 +/- 19) after pars plana vitrectomy (ppv) for vitreous opacities. Follow-up was 6 - 40 months (mean 19 +/- 9). Additional pathologies (except cataract) possibly affecting the functional outcome were present in 33 % (uveitis 8 %, premacular membrane 10 %, other 15 %). The technique consisted of a standard 3-port vitrectomy (44 % 25-gauge, 46 % 20-gauge). In 78 % ppv was combined with phacoemulsification + IOL implantation. RESULTS: Mean preoperative visual acuity was 0.6, postoperative 1.0 (+ 2.3 lines, p > 0.0001). One eye lost 2 lines. Peripheral retinal tears occurred in 11 %. Long-term complications (12 - 31 months) consisted of premacular membrane formation (1), luxation of the IOL/capsular bag. Secondary interventions included YAG capsulotomy (4) and glaucoma surgery (1). 94 % of all patients (98 % if additional pathologies were excluded) were satisfied with the outcome. CONCLUSIONS: Pars plana vitrectomy for vitreous opacities is safe and effective. Careful patient selection is crucial.

[Acute anterior non-granulomatous uveitis after intravitreal injection of bevacizumab]. / Akute anteriore nichtgranulomatöse Uveitis nach intravitrealer Bevacizumab-Injektion.

BACKGROUND: Recently, bevacizumab (Avastin(R)) has been used widely as a potential off-label treatment of CNV. The ocular side effects appear to be quite rare, but one concern is the risk of an inflammatory response. We report on an acute nong-ranulomatous anterior uveitis after intravitreal injection of bevacizumab. HISTORY AND SIGNS: A 74-year-old female with subfoveal CNV due to ARMD presented after the second injection of bevacizumab with a symptomatic acute non-granulomatous anterior uveitis. Work-up ruled out any other aetiology. THERAPY AND OUTCOME: Treatment with topical prednisolone and scopolamine resolved inflammation and symptoms. CONCLUSIONS: Intravitreal injection of bevacizumab is related with the possible development of acute non-granulomatous anterior uveitis, after having excluded infectious or other causes of uveitis unrelated to the bevacizumab injection. In recent clinical trials bevacizumab-induced uveitis has been demonstrated to be a rare event. The pathogenesis remains unclear. One possible explanation is the Fc portion of the antibody, which may offer the possibility of an increased cellular immune response. This case underlines the importance to inform patients about the possibility of such an episode.